Novo Nordisk A/S ADR diskutieren

Novo Nordisk A/S (NYSE: NVO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $160.00 price target on the stock.

Novo Nordisk A/S (NYSE: NVO) had its price target lowered by analysts at BMO Capital Markets from $170.00 to $160.00. They now have an "outperform" rating on the stock.

Novo Nordisk A/S (NYSE: NVO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $160.00 price target on the stock.

Novo Nordisk A/S (NYSE: NVO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $160.00 price target on the stock.

Novo Nordisk A/S (NYSE: NVO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $160.00 price target on the stock.

Novo Nordisk's looking like a real heavyweight in the pharma world, and I'm not just talking about their waistline-shrinking drugs! Their GLP-1 treatments are flying off the shelves faster than hot cakes at a weight loss convention. With Ozempic leading the charge and a 69% global market share, they're not just dipping their toes in the obesity market – they're making a big splash! The potential $130 billion obesity drug market by 2030 is like a golden ticket, and Novo's got their hand firmly on it. Their recent clinical trial results for Amycretin are turning heads too – it's like they've found the secret sauce for weight loss. Sure, there's some competition nipping at their heels, but Novo's pipeline is so packed, it's like they've got a crystal ball for the next decade of diabetes and obesity treatments. With their stock up 44% in a year, they're not just growing – they're ballooning (in a good way)! The only slim thing about Novo right now is the chance they'll slow down anytime soon. At this rate, they might just slim down the whole world before their growth does!